About EmeraMed
EmeraMed is a company based in Dublin (Ireland) founded in 2007. EmeraMed has raised $3.86 million across 4 funding rounds from investors including European Union and EIC Fund. EmeraMed has completed 1 acquisition, including CTI Science. EmeraMed offers products and services including Emeramide. EmeraMed operates in a competitive market with competitors including Captura Biopharma and metaLead, among others.
- Headquarter Dublin, Ireland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Emeramed Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.86 M (USD)
in 4 rounds
-
Latest Funding Round
$54.29 K (USD), Grant
Apr 30, 2020
-
Investors
European Union
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EmeraMed
EmeraMed offers a comprehensive portfolio of products and services, including Emeramide.
Drug that chelates heavy metals and reduces oxidative stress in the body.
People of EmeraMed
Unlock access to complete
Unlock access to complete
Funding Insights of EmeraMed
EmeraMed has successfully raised a total of $3.86M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $54.29 thousand completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EmeraMed
EmeraMed has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for EmeraMed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EmeraMed
EmeraMed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CTI Science.
Investment portfolio details for EmeraMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Focused on the development of therapeutics for the treatment of drug toxicity
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for EmeraMed
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - EmeraMed
Detailed financials for EmeraMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emeramed Comparisons
Peer comparison for EmeraMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EmeraMed
EmeraMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Captura Biopharma and metaLead, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic to eliminate harmful radioactive material from the body
|
|
| Locked | Locked | Locked |
Develops pharmaceutical candidates for toxic metal removal and rare disease treatments.
|
Detailed competitors of EmeraMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emeramed
Complete news archive for EmeraMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EmeraMed
EmeraMed was founded in 2007 and raised its 1st funding round 9 years after it was founded.
EmeraMed is headquartered in Dublin, Ireland.
EmeraMed is a funded company, having raised a total of $3.86M across 4 funding rounds to date.
EmeraMed was founded in 2007 in Dublin, Ireland, within the biotechnology sector. Therapeutics targeting mercury toxicity are being developed, including the metal chelator and antioxidant Irminix (Emeramide). Phase 2a trials were completed by January 23, 2016, with results expected. Marketing authorization is being pursued in the EU and US for mercury toxicity treatment. Approval for Irminix has been granted by the European Medicines Agency.
EmeraMed's top competitors include Captura Biopharma and metaLead.
EmeraMed offers Emeramide.
EmeraMed has made 1 acquisition, including CTI Science.
EmeraMed has 2 investors. Key investors include European Union, and EIC Fund.